Pacira BioSciences, Inc. $PCRX Shares Bought by Walleye Capital LLC

Key Points

• Walleye Capital LLC increased its holdings in Pacira BioSciences by 120.6% during the first quarter, owning 119,857 shares valued at approximately $2.98 million.
• Pacira BioSciences reported second-quarter earnings of $0.74 EPS, beating analyst estimates, with revenues of $181.1 million, although slightly below expectations of $183.11 million.
• Several hedge funds have also significantly increased their stakes in Pacira BioSciences, with institutional investors collectively owning 99.73% of the company's stock.

Walleye Capital LLC lifted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 120.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,857 shares of the company's stock after purchasing an additional 65,514 shares during the period. Walleye Capital LLC owned about 0.26% of Pacira BioSciences worth $2,978,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of PCRX. State of Wyoming grew its holdings in Pacira BioSciences by 8.0% in the fourth quarter. State of Wyoming now owns 6,566 shares of the company's stock valued at $124,000 after purchasing an additional 487 shares during the period. US Bancorp DE lifted its position in shares of Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after buying an additional 537 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock valued at $491,000 after acquiring an additional 794 shares during the period. Corton Capital Inc. grew its stake in Pacira BioSciences by 6.0% in the 4th quarter. Corton Capital Inc. now owns 21,575 shares of the company's stock valued at $406,000 after acquiring an additional 1,214 shares during the period. Finally, Ancora Advisors LLC purchased a new stake in Pacira BioSciences in the 4th quarter worth $26,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Needham & Company LLC decreased their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Truist Financial upgraded Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective on the stock in a report on Friday, July 25th. Finally, Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $30.83.

Pacira BioSciences Trading Up 2.1%

NASDAQ:PCRX traded up $0.55 during trading hours on Tuesday, hitting $27.22. The company had a trading volume of 800,697 shares, compared to its average volume of 735,409. Pacira BioSciences, Inc. has a 1 year low of $12.61 and a 1 year high of $27.64. The company has a market cap of $1.22 billion, a P/E ratio of -9.79 and a beta of 0.42. The company has a 50-day moving average of $23.78 and a 200 day moving average of $24.56. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The firm had revenue of $181.10 million for the quarter, compared to analysts' expectations of $183.11 million. During the same quarter in the previous year, the company posted $0.96 EPS. The company's revenue was up 1.7% compared to the same quarter last year. Pacira BioSciences has set its FY 2025 guidance at EPS. Sell-side analysts expect that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 5,578 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the transaction, the senior vice president directly owned 59,564 shares in the company, valued at approximately $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Marcelo Bigal sold 4,912 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director directly owned 11,393 shares of the company's stock, valued at approximately $269,672.31. This trade represents a 30.13% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.